Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sunovion
ClinicalTrials.gov Identifier:
NCT01458275
First received: October 20, 2011
Last updated: April 16, 2014
Last verified: April 2014

October 20, 2011
April 16, 2014
November 2011
March 2013   (final data collection date for primary outcome measure)
Change From Baseline in Average Daily Subject Reported AM and PM Reflective Total Nasal Symptom Scores (rTNSS) Over the 2-week Double-blind Treatment Period [ Time Frame: Weeks 0 - 2 ] [ Designated as safety issue: No ]
TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent 1 = mild 2 = moderate 3 = severe. Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.
The primary efficacy endpoint will be the change from baseline in average daily subject-reported AM and PM reflective total nasal symptom scores (rTNSS) over the 2-week double-blind treatment period [ Time Frame: Weeks 0 - 2 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01458275 on ClinicalTrials.gov Archive Site
  • Change From Baseline in Average Daily Subject-reported AM and PM Instantaneous Total Nasal Symptom Scores (iTNSS) Over the 2-week Double-blind Treatment Period [ Time Frame: Weeks 0 - 2 ] [ Designated as safety issue: No ]
    TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent 1 = mild 2 = moderate 3 = severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.
  • Change From Baseline in Average Daily Subject-reported AM and PM Reflective Total Ocular Symptom Scores (rTOSS) Over the 2-week Double-blind Treatment Period. [ Time Frame: Weeks 0 - 2 ] [ Designated as safety issue: No ]

    TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:

    0 = absent

    1. = mild
    2. = moderate
    3. = severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.
  • Change From Baseline in the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) Overall Score at the End of the Double-blind Treatment Period. [ Time Frame: Weeks 0 - 2 ] [ Designated as safety issue: No ]
    PRQLQ was developed to measure the functional problems (physical, emotional, and social) that are most troublesome to children with rhinoconjunctivitis. The PRQLQ has 23 questions in 5 domains (nose symptoms, eye symptoms, practical problems, activity limitation, and other symptoms). Children recalled how they were during the previous week and responded to each question on a 7-point scale (0 = not bothered to 6 = extremely bothered or 0 = none of the time to 6 = all of the time) for a total possible score of 138. The overall PRQLQ score is the mean of all 23 responses and the individual domain scores are the means of the items in those domains.
  • Change From Baseline in Average Daily Subject Reported AM Instantaneous Total Nasal Symptom Scores (iTNSS) Over the 2-week Double-blind Treatment Period [ Time Frame: Weeks 0 - 2 ] [ Designated as safety issue: No ]
    TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions assessed in the AM. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent 1 = mild 2 = moderate 3 = severe in the AM. Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.
  • Change From Baseline in Average Daily Subject-reported AM and PM Instantaneous Total Ocular Symptom Scores (iTOSS) Over the 2-week Double-blind Treatment Period. [ Time Frame: Weeks 0 - 2 ] [ Designated as safety issue: No ]

    TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:

    0 = absent

    1. = mild
    2. = moderate
    3. = severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement
  • Time to Maximal Effect in the AM and PM Reflective Total Nasal Symptom Scores (rTNSS) Over the 2-week Double-blind Treatment Period [ Time Frame: Weeks 0 - 2 ] [ Designated as safety issue: No ]
    The time to maximal effect, defined as the number of days until the first treatment day on which the estimated difference between ciclesonide nasal aerosol and placebo was at least 90% of the largest estimated difference, was based on the analyses of change from baseline in the average of AM and PM rTNSS scores for each day. The time to achieve at least 90% of these estimated differences is presented.
  • Number of Subjects Experiencing Treatment-emergent AEs [ Time Frame: Weeks 0 - 3 ] [ Designated as safety issue: No ]
    Treatment-Emergent Adverse Events Occurring in ≥ 2% of Subjects in Any Treatment Group (ITT Population)
  • Percentage of Subjects Experiencing Treatment-emergent AEs [ Time Frame: Weeks 0 - 3 ] [ Designated as safety issue: No ]
    Treatment-Emergent Adverse Events Occurring in ≥ 2% of Subjects in Any Treatment Group (ITT Population)
  • Treatment-emergent AEs Causing Study Medication Discontinuation [ Time Frame: Weeks 0 - 3 ] [ Designated as safety issue: No ]
  • Number of Subjects Experiencing Treatment-emergent Nasal AEs, Including Epistaxis, Nasal Ulceration, and Nasal Perforation [ Time Frame: Weeks 0 - 3 ] [ Designated as safety issue: No ]
  • Percentage of Subjects Experiencing Treatment-emergent Nasal AEs, Including Epistaxis, Nasal Ulceration, and Nasal Perforation [ Time Frame: Weeks 0 - 3 ] [ Designated as safety issue: No ]
  • Change from baseline in average daily subject-reported AM and PM instantaneous total nasal symptom scores (iTNSS) over the 2-week double-blind treatment period [ Time Frame: Weeks 0 - 2 ] [ Designated as safety issue: No ]
  • Change from baseline in the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) overall score at the end of the double-blind treatment period. [ Time Frame: Weeks 0 - 2 ] [ Designated as safety issue: No ]
  • Change from baseline in average daily subject-reported AM and PM reflective total ocular symptom scores (rTOSS) over the 2-week double-blind treatment period. [ Time Frame: Weeks 0 - 2 ] [ Designated as safety issue: No ]
  • Change from baseline in subject reported AM iTNSS over the 2-week double blind treatment period. [ Time Frame: Weeks 0 - 2 ] [ Designated as safety issue: No ]
  • Change from baseline in average daily subject-reported AM and PM instantaneous total ocular symptom scores (iTOSS) over the 2-week double-blind treatment period. [ Time Frame: Weeks 0 - 2 ] [ Designated as safety issue: No ]
  • Time to maximal effect. [ Time Frame: Weeks 0 - 2 ] [ Designated as safety issue: No ]
  • Number and percentage of subjects experiencing treatment-emergent AEs, treatment-emergent SAEs, and treatment-emergent AEs causing study medication discontinuation. [ Time Frame: Weeks 0 - 3 ] [ Designated as safety issue: No ]
  • Number and percentage of subjects experiencing treatment-emergent nasal AEs, including epistaxis, nasal ulceration, and nasal perforation. [ Time Frame: Weeks 0 - 3 ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)
A 2-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6 to 11 Years With Seasonal Allergic Rhinitis

This is a 2-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, efficacy and safety study of ciclesonide nasal aerosol administered once daily to male and premenarchal female subjects 6 to 11 years-old diagnosed with SAR.

This is a 2-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, efficacy and safety study of ciclesonide nasal aerosol administered once daily to male and premenarchal female subjects 6 to 11 years-old diagnosed with SAR.

This study will consist of the following:

Screening, Single-blind Placebo Run-in period, Double-blind Treatment period (during this period, subjects will be randomized to double-blind treatment with either ciclesonide nasal aerosol 37 mcg or 74 mcg or placebo for 2 weeks of treatment) and Follow-up. The total duration of subject participation will be approximately 2 months.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Seasonal Allergic Rhinitis
  • Drug: Ciclesonide nasal aerosol 37 mcg
    ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37 mcg
  • Drug: ciclesonide nasal aerosol 74 mcg
    ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
  • Drug: Placebo
    Placebo - one actuation per nostril
  • Active Comparator: ciclesonide nasal aerosol 37mcg
    ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37 mcg
    Intervention: Drug: Ciclesonide nasal aerosol 37 mcg
  • Active Comparator: ciclesonide nasal aerosol 74 mcg
    ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
    Intervention: Drug: ciclesonide nasal aerosol 74 mcg
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
847
March 2013
March 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Gives written informed consent (parent/legal guardian) and assent (from the child), including privacy authorization as well as adherence to concomitant medication withholding periods, prior to participation.
  • Is a male or premenarchal female 6 to 11 years-old at the screening.
  • Is in general good health (defined as the absence of any clinically relevant abnormalities as determined by the investigator) based on screening physical examination and medical history.
  • Has a history of SAR to any relevant dominant seasonal allergen for a minimum of one to two years immediately preceding the study Screening Visit. The SAR must have been of sufficient severity to have required treatment (either continuous or intermittent) in the past and is expected to require treatment throughout the entire study period.
  • Has a demonstrated sensitivity to a relevant dominant seasonal allergen known to induce SAR based on a documented result with a standard skin prick test either within 12 months prior to screening or performed at the screening visit. A positive test is defined as a wheal diameter at least 3 mm larger than the control wheal (normal saline) for the skin prick test. The subject's positive allergen test must be consistent with the medical history of SAR, and the allergen must be present in the subject's environment throughout the study.
  • Subject or parent/guardian must possess an educational level and degree of understanding of English that enables them to communicate suitably with the Investigator and study coordinator as well as accurately complete both the Allergic Rhinitis diary and Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ).

Exclusion Criteria:

  • Has a history of physical findings of nasal pathology, including nasal polyps or other clinically significant respiratory tract malformations; recent unhealed nasal biopsy; nasal trauma; or nasal ulcers or perforations. Surgery and atrophic rhinitis or rhinitis medicamentosa are not permitted within the 120 days prior to the screening visit.
  • Has evidence of infection, significant anatomic abnormality, ulceration of the mucosa, blood in the nose, or any other clinically relevant finding on nasal examination at the screening visit.
  • Has nasal jewelry
  • Has participated in any investigational drug trial within the 30 days preceding the screening visit or is planning participation in another investigational drug trial at any time during this trial.
  • Has a known hypersensitivity to any corticosteroid or any of the excipients in the formulation of ciclesonide.
  • Has a history of a respiratory infection or disorder, including but not limited to bronchitis, pneumonia, influenza, and severe acute respiratory syndrome (SARS), within the 14 days preceding the screening visit.
  • Has active asthma requiring treatment with inhaled or systemic corticosteroids and/or routine use of beta-agonists and any controller drugs (eg, theophylline, leukotriene antagonists); intermittent use (≤ 3 uses per week) of inhaled short-acting beta-agonists is acceptable. Use of short-acting beta agonists for exercise induced bronchospasm will be allowed.
  • Plans to travel outside the study area (the known pollen area for the investigative site) for 2 or more consecutive days between Randomization Visit and the final Treatment Visit.
  • Plans to leave the study area (the known pollen area for the investigative site) for longer than 24 hours during the Single-blind Placebo Run-in period.
  • Is expecting to use any disallowed concomitant medications during the treatment period.
  • Is planning initiation of immunotherapy during the study period or dose escalation during the study period. However, initiation of immunotherapy 90 days or more prior to the screening visit and use of a stable (maintenance) dose (30 days or more) may be considered for inclusion.
  • Has nonvaccinated exposure to or active infection with chickenpox or measles within the 21 days preceding the screening visit.
  • Initiates pimecrolimus cream 1% or greater or tacrolimus ointment 0.03% or greater during the study period or plans a dose escalation during the study period. However, initiation of these creams/ointments 30 days or more prior to screening and use of a stable (maintenance) dose during the study period may be considered for inclusion.
  • Is a child or relative of any clinical investigator or site personnel, even those who are not directly involved in this study.
  • Has any of the following conditions that are judged by the investigator to be clinically significant and/or to affect the subject's ability to participate in the clinical trial: impaired hepatic function; history of ocular disturbances, eg, glaucoma or posterior subcapsular cataracts or herpes simplex; any systemic infection hematological (including anemia), hepatic, renal, endocrine disease; gastrointestinal disease; malignancy (excluding basal cell carcinoma); current neuropsychological condition with or without drug therapy. Any behavioral condition that could affect subject's ability to accurately report symptoms to the caregiver such as developmental delay, attention deficit disorder, and autism.
  • Has any condition that, in the judgment of the investigator, would preclude the subject from completing the protocol with capture of the assessments as written.
  • Has received ciclesonide nasal aerosol in a previous clinical trial
Both
6 Years to 11 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01458275
SEP060-305
No
Sunovion
Sunovion
Not Provided
Study Director: Respiratory Medical Director, MD Sunovion
Sunovion
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP